Home / 2019 / November / 14

Daily Archives: November 14, 2019

Philips employees and Philips Foundation join forces in the fight on childhood pneumonia

November 14, 2019

Focused program of partnerships, collaboration, funding and volunteering addresses the community-level prevention, diagnosis and treatment of a disease that takes the lives of around 800,000 under-five-year-olds each year, mostly in disadvantaged communities.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the Philips Foundation, with its mission to reduce healthcare inequality by providing access to quality healthcare for disadvantaged communities, today announced the achievements of a year-long program of collaborations to reduce infant mortality rates for childhood pneumonia, a disease that currently claims the lives of around 800,000 under-five-year-olds a year [1] – equivalent to one every 39 seconds.

Combining the volunteering activities of Philips’ 80,000 employees, local stakeholder engagement, accessible and affordable technology, and the scale-up capabilities of international NGOs, this childhood pneumonia program exemplifies the Philips Foundation’s commitment to drive and support initiatives that deliver long-term system change and achieve lasting impact. During the past 12 months, the program is estimated to have created access to better care for more than 700,000 people, in countries as widespread as Afghanistan, Ethiopia, Nicaragua, Malawi and India.

“The mission of the Philips Foundation is to reduce healthcare inequality by providing access to quality healthcare for disadvantaged communities,” said Ronald de Jong, Chairman of the Philips Foundation Board. “Focusing our year-long volunteering efforts on a single global healthcare issue that disproportionately affects disadvantaged communities, created a multiplier effect, supporting ways to overcome the challenges, and ensuring long-term impact.”

Childhood pneumonia
Pneumonia in children under five was chosen as the 2018-2019 topic for Philips’ employee volunteering, due to its many casualties, and the fact that respiratory disease is one of the expert fields of Philips that the foundation can tap into. Caused by viral, bacterial, or fungal infection of the lungs, childhood pneumonia can be prevented by immunization, a healthier diet and improved environmental conditions [2] – for example, better (indoor) air quality. Although bacterial pneumonia can be effectively treated with low-cost antibiotics, only a third of children receive them in time [2]. The accurate determination of rapid breathing, which is the principal early indicator of childhood pneumonia, can be achieved by leveraging the power of artificial intelligence (AI) in affordable diagnostic devices.

Examples of the supported and initiated activities of the Philips Foundation over the past 12 months, conducted through global partnerships, local projects and support of social entrepreneurs, are listed below:

  • Save the Children and ZMQ in India – VISHWAAS (Breath of Hope) project: This program is aimed at developing and proving a low-cost innovative approach in India for the prevention, diagnosis and treatment of childhood pneumonia, including an app-based solution to improve awareness of the means of prevention and care-seeking practices in affected communities.
  • Partnership with Ashoka Fellow Hilmi Quraishi, ZMQ – the MIRA Channel project on childhood pneumonia: This project addresses the knowledge gap in childhood pneumonia through a series of short digital stories embedded in a larger ‘Maternal & Child Health’ mobile-based platform called MIRA.
  • The Malaria Consortium BREATHE (Breath REcognition Aid to Health Experts) project: This study aims to assess the reliability of a video annotation tool for counting respiratory rate, which has the potential to be used as a new reference standard for measuring the performance of new automated respiratory rate diagnostic aids to support the diagnosis of pneumonia in children under five in low resource settings.
[1] data.unicef.org/topic/child-health/pneumonia
[2] www.who.int/news-room/fact-sheets/detail/pneumonia

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Yannick Eshuijs
Philips Foundation
Tel. : +31 6 18526633
E-mail: yannick.eshuijs@philips.com
Twitter: @PhilipsFDN

About the Philips Foundation
The Philips Foundation is a registered charity that was established in July 2014 as the central platform for Philips’ CSR activities. Reflecting our commitment to United Nations Sustainable Development Goals 3 (Ensure healthy lives and promote well-being for all at all ages) and 17 (Revitalize the global partnership for sustainable development), the mission of the Foundation is to reduce healthcare inequality by providing access to quality healthcare for disadvantaged communities. We do this by deploying Philips’ expertise, innovative products and solutions, by collaborating with key partners around the world and by providing financial support for collaborative activities. More information on the Philips Foundation can be found at www.philips-foundation.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Imperial Capital Hires Mark Green As Head of Special Situations & Structured Credit

LOS ANGELES, Nov. 14, 2019 (GLOBE NEWSWIRE) — Imperial Capital, LLC (“Imperial Capital”), today announced that Mark Green has joined the firm as the Head of Special Situations and Structured Credit.   Based in New York, Mr. Green will be responsible for expanding Imperial Capital’s credit sales, trading and investment banking efforts further through credit event-driven situations, structuring expertise and investment strategies designed to allow clients to develop valuable solutions to issues they face and benefit from market opportunities across a range of asset classes.

“Mark has an exceptional track record of investing, leading teams and building businesses, and we are excited to have him join our firm.  Structured credit is an important strategic priority and Mark brings with him strong transaction experience, client relationships, and is the right partner to drive growth. Having worked with him in the past, I know he will bring a new competitive edge and expand our credit capabilities for clients,” said Tim Sullivan, Head of US Credit.

Mr. Green said, “I am thrilled to join Imperial Capital and grateful for the opportunity to lead this business. The firm is well positioned to expand its capabilities and I look forward to providing innovative and strategic solutions to clients while pursuing attractive risk adjusted returns for Imperial Capital’s current and future investors.”

Prior to joining Imperial Capital, Mr. Green was the Managing Partner and Chief Investment Officer of Chatham Road Capital, a credit-focused investment firm he co-founded that exploited market imbalances and inefficiencies in the public and private markets.    Prior to the formation of Chatham Road Capital, Mr. Green served as a Managing Director at Leucadia National Corporation, where he managed Leucadia’s real estate principal and special situations investment activities.  In addition, Mr. Green headed the original build out of Jefferies Group’s (a subsidiary of Leucadia) CRE platform and was integral in the formation of Jefferies LoanCore, LLC, a broad-based finance company, that originated commercial real estate debt-related products throughout the US and UK.

Prior to joining Leucadia and Jefferies, Mr. Green served as a senior executive in the real estate groups of UBS, Eurohypo AG and CIBC World Markets and also held positions at The Blackstone Group and Ernst & Young.

Mr. Green earned an MBA from Columbia Business School and a BS degree from Skidmore College.

About Imperial Capital, LLC

Imperial Capital, LLC is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer’s capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital, LLC has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital, LLC can be found at www.imperialcapital.com.

For more information regarding Imperial Capital, please contact:
Mark Martis
+1 310 246 3674
mmartis@imperialcapital.com

About Imperial Capital (International), LLP

Imperial Capital International, founded in 2011, is an affiliate of Imperial Capital, LLC with an office in central London.  Complementing Imperial Capital’s existing corporate credit sales and trading franchise, Imperial Capital International expanded the Imperial Capital franchise into the EEA.  The company focuses on the entire credit spectrum and takes a full capital structure research approach to supplement sales and trading services to its European institutional clients.

For more information regarding Imperial Capital (International), LLP, please contact:
Emma McClintock
+ 44 (0) 207 650 5429
emcclintock@imperialcapital.com

Novel therapeutic approach to cardiovascular disease from SENS Research Foundation flagship research program graduates from laboratory to the biotech world

Kizoo Technology Capital leads seed round financing at Underdog Pharmaceuticals

SRF announces leadership appointments

MOUNTAIN VIEW, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — Underdog Pharmaceuticals, Inc. (Underdog), and SENS Research Foundation (SRF) today announced the launch of Underdog and the completion of its seed round, providing $3.95 million to promote Underdog’s development of disease-modifying treatments for atherosclerosis and other age-related diseases. SRF also announced two senior appointments.

The Underdog round is led by Michael Greve’s Kizoo Technology Capital, part of the Forever Healthy Group and one of the premier organizations focusing on accelerating rejuvenation biotechnologies. It also includes Oculus co-founder Michael Antonov through Tubus, LLC, and financier Harald McPike through Chambray Worldwide, Ltd.

Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D. and Michael Kope, formerly the V.P. of Research and the founding CEO, respectively, of SRF.

“We’ve taken a well-known and extremely safe compound,” said O’Connor, “and have created novel derivatives that can specifically target the toxic biomolecule that drives the development of atherosclerosis, the cause of most heart attacks and strokes.”

Underdog’s research has combined computational and synthetic chemistry programs to create custom-engineered cyclodextrins (polysaccharides with known industrial and pharmaceutical excipient uses) to capture, and remove from cells, oxidized cholesterol derivatives such as 7-ketocholesterol, which are broadly toxic molecules with no known biological function. “Underdog will take a classic pharmaceutical approach and use it to attack the root causes of cardiovascular disease,” said Kope.  “If we’re successful, we won’t just be ameliorating the disease, but reversing it.”

Underdog’s advisors include world-renowned cyclodextrin expert Dr. Lajos Szente. “This elegant approach has the potential to be truly revolutionary,” Szente said. “I’m delighted to be working with them on this important advancement in the field.”

“I came to Aubrey de Grey years ago so that we could work together to accelerate the availability of human rejuvenation therapies,” said Greve. “I am proud to help SRF grow a flagship research program into a genuine company and to help unlock the required capital to develop a true rejuvenation therapy. I’m gratified that we’ve done this while continuing to allow for the health and growth of SRF itself, one of our most important engines for the rejuvenation pipeline.”

The agreement between the organizations will provide equity, royalties, and milestones for the future support of SRF programs.

As Underdog spins out, the V.P. of Research position at SRF has been assumed by Prof. Alexandra Stolzing. Stolzing, a long-standing SRF Research Advisory Board member, received her PhD from the Humboldt University in Berlin, was a postdoctoral fellow at Sheffield University, UK, group leader at the Fraunhofer Institute for Cell Therapy and Immunology, Germany, and then Professor for Biogerontological Engineering at Loughborough University, UK. With over 70 peer-reviewed publications, she has participated in several international research consortia in areas including regenerative medicine, cell and gene therapy development, and neurodegenerative diseases. Her industry experience includes startup CSO and VP of Research roles. Said Stolzing, “I’ve always been passionate about translational research in aging, and I’m very excited to join SRF, where I look forward to translating SRF’s basic science projects, initiating new projects, and helping generate the next wave of healthspan spinouts.”

Science and technology investor and longtime SRF board member Jim O’Neill has stepped in to lead the SENS Research Foundation as interim CEO. He will also spearhead the search for the incoming permanent CEO. O’Neill has advised, invested in, and nurtured more than sixty science and technology companies. While running the Thiel Foundation, he co-founded the Thiel Fellowship and helped create deep science fund Breakout Labs. Previously, he helped lead the U.S. Department of Health and Human Services as the principal associate deputy secretary, where he was responsible for overseeing policy and regulations at NIH, FDA, and CDC and led two major reforms of FDA. He supported the creation of the Armed Forces Institute for Regenerative Medicine, served on the steering committee of the Biomedical Advanced Research and Development Authority, and represented the United States on the U.S. delegation to the World Health Assembly. “Over the past decade, Mike and Aubrey built a team of scientists dedicated to damage repair and turned skeptics into advocates along the way,” said O’Neill. “The growing interest in technologies that can reverse aging is proof of their vision and determination. I’m excited to advance SRF’s vision to bring the benefits of such technologies to the public.”

“This is an historic moment for SENS Research Foundation,” said Dr. Aubrey de Grey, co-founder and Chief Science Officer of SRF. “Underdog may well become one of the most significant endeavors in the rejuvenation biotechnology industry, and Mike and Oki are the perfect team to make it a success. And with Jim’s deep experience in investment and policy, and Alex’s brilliance in research and teaching, I’ve no doubt our mission is in good hands. I’m delighted to have their leadership and expertise at SRF.”

About Underdog

Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol using rationally designed molecules to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease created through a SENS Research Foundation program. For more information, please visit underdogpharma.com.

About SENS Research Foundation

SENS Research Foundation is a 501(c)(3) nonprofit that works to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging.  SRF supports research projects focused on a damage repair paradigm at universities and institutes around the world with the goal of curing such age-related diseases as heart disease, cancer, and Alzheimer’s disease. SRF educates the public and trains researchers to support a growing regenerative medicine field through advocacy campaigns and educational programs. For more information, please visit sens.org.

About Kizoo

Kizoo provides mentoring and seed and early-stage financing with a focus on rejuvenation biotechnology. Having been entrepreneurs, VCs, and mentors in both high-growth tech and biotech companies for many years, with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech – a young industry that will eventually become much bigger than today’s largest technology markets.

As part of the Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include AgeX, FoxBio, Turn.bio, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, and others. Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference. For more information, please visit: kizoo.com and forever-healthy.org.

Notice:
This press release is not an offer to sell or a solicitation of an offer to buy securities in any jurisdiction.  No securities commission or regulatory authority has approved or disapproved the information contained herein.
Media contacts:

For Underdog: press@underdogpharma.com

For SRF: media@sens.org
For Kizoo: fs@kizoo.com

ENLITIC CLOSES $25 MILLION IN SERIES B-1 FUNDING ROUND

New Equity Capital Fuels Momentum as Company Sets its Sights on Market Deployment in 2020, Lawrence Gozlan Joins Board of Directors

San Francisco, Nov. 14, 2019 (GLOBE NEWSWIRE) — Enlitic, Inc., a leading developer of artificial intelligence (AI) software designed to help doctors diagnose patient conditions more quickly and more accurately, announced today the completion of $25 million in Series B-1 financing. Thorney Investment Group, one of Australia’s leading investment groups, led the round and Enlitic’s existing investors – Capitol Health, Marubeni Corporation, Amplify Partners, The Jagen Group, and Regal Funds Management – also participated. Enlitic will use the proceeds for the next phase build-out of its comprehensive AI software platform and to further grow its global footprint with major regional partners in the healthcare industry, paving the way for market deployment in 2020. The company will debut its new platform in December at RSNA 2019.

Enlitic also announced the appointment of Lawrence Gozlan of The Jagen Group to the company’s board of directors, joining Sunil Dhaliwal of Amplify partners, Andrew Harrison of Capitol Health, Kevin Lyman, Enlitic’s Chief Executive Officer, and Michael Sistenich, Enlitic’s Chairman of the Board.

In building the company’s best-in-class platform, Enlitic’s team of practicing radiologists, data scientists, and software engineers analyze millions of clinical cases from global healthcare partners to improve diagnostic accuracy, speed, and patient outcomes, as well as to accelerate pharmaceutical research and drug trials. Since undergoing an executive reorganization in June of 2018 that included the appointment of Kevin Lyman as Chief Executive Officer, Anthony Upton as Chief Medical Officer, and Michael Sistenich as Chairman of the Board, Enlitic has experienced unprecedented growth that includes the following achievements:

  • In April, Enlitic announced that it had completed its Series B funding with a $15 million raise.
  • Also, in April, the company signed a significant joint development agreement with Marubeni Corporation and global imaging company, Konica-Minolta, that streamlines Enlitic’s expansion efforts in the Asian market.
  • In August, Enlitic announced that it had rounded out its core leadership team by appointing a Chief Financial Officer and heads of Research & Development, Business Development, Regulatory & Quality Assurance, Creative, and Communications. The company also opened a new office in New York City.
  • In October, the company announced a partnership with Select Healthcare Solutions, a healthcare technology and services provider that owns and operates cancer centers across the U.S. The partnership provides Enlitic with high-quality data to accelerate its research into the early detection of most forms of cancer and will help drive the company’s development of best-in-class workflow solutions for oncology centers around the world.

“Enlitic’s rapid growth, including our successful fundraising, points to the enthusiasm and confidence we have elicited in the marketplace with the development of our comprehensive AI software platform and our highly efficient business model,” said Kevin Lyman, Enlitic’s Chief Executive Officer. “We look forward to formally debuting our platform at RSNA 2019 in December and to its market deployment in 2020.”

Alex Waislitz, Founder and Chairman of Thorney Investment Group said, “The global healthcare industry is experiencing the dawn of a new age with artificial intelligence and we are excited to be at its forefront with our investment in Enlitic and the company’s game changing AI-powered software platform.”

Commenting on the appointment of Lawrence Gozlan to Enlitic’s board of directors, Michael Sistenich, Enlitic’s Board Chairman said, “Lawrence joins us with one of the most extensive backgrounds in the biotechnology and healthcare investment communities. I am certain that his expertise and keen eye to the future of global healthcare will add tremendous value to our board.”

About Enlitic

Named one of the world’s “50 Smartest Companies” by MIT Technology Review, Enlitic is a pioneer in medical deep learning, building a best-in-class platform that bridges human and artificial intelligence to save time, money, and ultimately, lives. The company’s team of practicing radiologists, data scientists, and software engineers analyze a vast stream of healthcare data –– including millions of clinical cases from cross-sector healthcare partners –– to improve diagnostic accuracy, speed, and patient outcomes, as well as to accelerate pharmaceutical research and drug trials. Enlitic is based in San Francisco and has offices in New York and Sydney, Australia. Find out more at www.enlitic.com, and follow the company on Twitter, and LinkedIn.

John Ordoña
Enlitic
jordona@enlitic.com

Philips announces first installation of IntelliSpace Critical Care and Anesthesia system at Kasih Ibu Hospital in Bali, Indonesia

November 14, 2019

Philips interoperable digital technology, predictive trend analytics and smart algorithms help drive improved outcomes in acute care

Amsterdam, the Netherlands and Jakarta, Indonesia  – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant development in the digitization of patient treatment in Indonesia, with the country’s first installation of Philips IntelliSpace Critical Care and Anesthesia (ICCA) system at the Kasih Ibu Hospital in Denpasar, Bali. The critical care technology is part of Philips’ broader connected care suite aimed to help ensure seamless care and timely information flow between patients and the healthcare professionals who provide treatment. At Kasih Ibu Hospital, the critical care system will be integrated with Philips Patient Deterioration Solution – a portfolio of solutions to help manage patient deterioration outside the ICU – to better track patient conditions, helping the hospital achieve improved patient care, enhanced patient experience, lower costs and better staff satisfaction.

Leveraging digital technology to help advance acute critical care
The Intensive Care Unit (ICU) workflow is quite complex, involving admission/discharge, daily routine care, emergency, and unscheduled events, as well as managing end of life care. The sheer numbers of medications, scans, treatments, and tests administered pose a huge burden on patients and their loved ones, and the complex workflow demands a huge effort from all clinical teams involved. It is estimated there are 178 processes delivered to each ICU patient per day, with 1.7 of them associated with some error [1]. For those teams, decision-making becomes a complex yet time-critical process, made even more difficult by data-overload caused by disparate devices, patient record systems and data sources.

Digitization of healthcare services, especially in hospitals treating emergency and post-surgical patients, is a pressing need worldwide as hospitals cope with meeting surging healthcare demand while not compromising the quality of care and patient safety. As hospitals across the globe team with industry to improve and save lives, Indonesia is no exception. Acute care is particularly challenging, associated with the highest number of medical errors. Nearly all ICU patients suffer a potentially life-threatening error during their stay, with medication errors accounting for 78% of serious medical errors [2]. Decision-making and diagnosis are also more difficult in critical care due to the vulnerability of patients, who can have co-morbidities and deteriorate rapidly.

“Philips is helping to shape the future of healthcare by providing smart patient care and clinical intelligence where and when needed,” said Carla Kriwet, Chief Business Leader of Connected Care at Philips. “With solutions like Philips IntelliSpace Critical Care and Anesthesia, we are combining patient monitoring with connected technology, to help deliver more consistent patient care, seamless patient transitions and improved care. We are committed to help hospitals across Indonesia apply connected care technology to help both patients and medical teams.”

“Kasih Ibu Hospital aspires to become a smart hospital, at the forefront of leveraging health technology innovations, especially in digitization of patient care, in order to meet domestic and foreign patient expectations,” said Krishnawenda Duarsa, President of Kasih Ibu Hospital Group. “We believe our investment in these solutions will help improve our service quality and patient treatment, allowing our medical staff to focus on providing the right care at the right time to help drive improved patient outcomes and better operational efficiency.”

Interoperable digitalized hospital systems for faster and more accurate treatment
Philips IntelliSpace Critical Care and Anesthesia is an advanced clinical decision support and automatic documentation solution, providing analytics, integrated care management and reporting throughout the ICU care cycle. The system centralizes and organizes patient data – including admission documents, vital signs, labs, and consult notes – to help transform patient data into actionable insights, enabling connectivity between medical devices in the ICU to help improve outcomes.

Early Warning Scoring leads to identification of clinical deterioration
The Philips Patient Deterioration Solution consists of an integrated suite of devices, wearable sensors, software, and professional services. The customizable solution is integrated with the hospital EMR (electronic medical record) to help enhance organizational efficiencies and current infrastructure investments.  The solution aims to enable caregivers to effectively identify and proactively respond to patient deterioration in hospital wards, help reduce the risk of missed signs of deterioration, improve patient care, and increase efficiencies in patient management and workflow [3].

Leveraging intelligent algorithms and predictive trend analytics, the solution, including IntelliVue GuardianSoftware, helps clinicians identify patient deterioration, notify caregivers and enable appropriate, timely intervention to prioritize patient care. As part of Philips’ goal of improving the lives of 3 billion people a year by 2030, more than 275 million patients are monitored with Philips’ patient monitors each year. Abnormal vital signs or other indications of clinical instability typically appear eight to twelve hours prior to critical event [3]. Through the use of Philips IntelliVue Guardian Software, an automated early warning scoring (EWS) and workflow system, clinicians receive information to help identify subtle warning signs of a patient’s physiological decline for timely intervention.

[1] Donchin, Y. et al. A look into the nature and causes of human errors in the intensive care unit. BMJ Qual. Saf. 12, 143–147 (2003).
[2] Rothschild, J. M. et al. The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care. Crit. Care Med. 33, 1694–1700 (2005).
[3] Early warning scoring can aid in identifying subtle warning signs of physiological decline 6 to 8 hours before an event (Incidence, staff awareness and mortality of patients at risk on general wards. Fuhrmann L, Lippert A, Perner A, Østergaard D. Resuscitation. 2008 Jun;77(3):325-30. Epub 2008 Mar 14. PMID: 18342422 [PubMed – indexed for MEDLINE])
[4] http://www.euro.who.int/en/health-topics/Health-systems/patient-safety/data-and-statistics

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail: Kathy.oreilly@philips.com
Twitter: @kathyoreilly

Yulin Febrina
Philips Indonesia
Tel: +62 2965 1330
E-mail: yulin.febrina@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

New Research Finds Consumers Are 35x More Likely To Open Mobile Messages Than Emails

STOCKHOLM, Sweden; SEATTLE, USA. 14/11/ 2019 – Consumers welcome many types of personalized mobile messages from businesses, and they are 35x more likely to open mobile messages than emails, reports a new global study from Sinch. Despite this, businesses have been slow to provide the type of high-value, real-time messaging that consumers prefer most.

The Sinch Mobile Consumer Engagement 2020 report uncovers a clear “opportunity gap” between how consumers use messaging today, versus how they would like to use it. For example, 62% of consumers would like to confirm service appointments via messaging, though just 41% do so today. And 70% want banks to message them about suspicious activity in their accounts, yet only 35% receive those today. This type of gap exists across verticals and regions.

“CX leaders understand that even with access to dozens of channels to reach customers, they must use restraint and find the right touch points for each individual,” says Jonathan Bean, CMO at Sinch, a global leader in messaging, voice and video. “For many, mobile messaging is still a new ecosystem, but the research shows consumers are open and willing to engage with businesses through mobile messaging, so long as businesses provide high-value information that’s personalized.”

Gathering insights from 2,300 consumers across the globe and perspectives from leaders in customer engagement at brands including Oracle, Uber and Adobe, Sinch explores the messaging scenarios consumers find useful and welcome — and those where they experience great trepidation. Key findings include:

People put up with unread emails, not unread mobile messages: 40% of consumers say they have at least 50 unread emails in their inbox — but just 4% say the same about mobile messages.

Consumers wary about app downloads: 80% of consumers say they’ll only download an app from a company they know and trust, and 72% are concerned apps are tracking their movements. This wariness is an important consideration for businesses investing in branded app development.

Mobile users ready for rich engagement: Best-in-class companies are experimenting with personalized video, rich media messaging and AI-fueled conversations — and consumers are pleased with the results. For example, 2 in 3 who have used a chatbot report a positive experience, citing speed and efficiency, and most saying the chatbot served them as well or better than a human agent.

The global study of 2,300 consumers was fielded in August 2019, and examines current and desired use of mobile messaging, attitudes about data privacy, acceptance of chatbots and channel preferences.

To download a copy of Mobile Consumer Engagement 2020, visit https://www.sinch.com/insights/downloads-and-reports/mobile-consumer-engagement-2020/

Sinch provides cloud-based connections between businesses and their customers. Through messaging, voice and video, Sinch handles 25 billion API transactions annually. Eight of the world’s 10 largest US tech enterprises (by market capitalization), as well as major airlines, rail, ridesharing and parcel delivery services around the world rely on Sinch for personalized, seamless and secure mobile connections. Find out more at Sinch.com or connect on Facebook, LinkedIn, Twitter or Instagram.

Media Contact:
Name: Jeff Hasen                                                       
Email: Jeff.Hasen@sinch.com

Attachment

New Research Finds Consumers Are 35x More Likely To Open Mobile Messages Than Emails

STOCKHOLM, Sweden; SEATTLE, USA. 14/11/ 2019 – Consumers welcome many types of personalized mobile messages from businesses, and they are 35x more likely to open mobile messages than emails, reports a new global study from Sinch. Despite this, businesses have been slow to provide the type of high-value, real-time messaging that consumers prefer most.

The Sinch Mobile Consumer Engagement 2020 report uncovers a clear “opportunity gap” between how consumers use messaging today, versus how they would like to use it. For example, 62% of consumers would like to confirm service appointments via messaging, though just 41% do so today. And 70% want banks to message them about suspicious activity in their accounts, yet only 35% receive those today. This type of gap exists across verticals and regions.

“CX leaders understand that even with access to dozens of channels to reach customers, they must use restraint and find the right touch points for each individual,” says Jonathan Bean, CMO at Sinch, a global leader in messaging, voice and video. “For many, mobile messaging is still a new ecosystem, but the research shows consumers are open and willing to engage with businesses through mobile messaging, so long as businesses provide high-value information that’s personalized.”

Gathering insights from 2,300 consumers across the globe and perspectives from leaders in customer engagement at brands including Oracle, Uber and Adobe, Sinch explores the messaging scenarios consumers find useful and welcome — and those where they experience great trepidation. Key findings include:

People put up with unread emails, not unread mobile messages: 40% of consumers say they have at least 50 unread emails in their inbox — but just 4% say the same about mobile messages.

Consumers wary about app downloads: 80% of consumers say they’ll only download an app from a company they know and trust, and 72% are concerned apps are tracking their movements. This wariness is an important consideration for businesses investing in branded app development.

Mobile users ready for rich engagement: Best-in-class companies are experimenting with personalized video, rich media messaging and AI-fueled conversations — and consumers are pleased with the results. For example, 2 in 3 who have used a chatbot report a positive experience, citing speed and efficiency, and most saying the chatbot served them as well or better than a human agent.

The global study of 2,300 consumers was fielded in August 2019, and examines current and desired use of mobile messaging, attitudes about data privacy, acceptance of chatbots and channel preferences.

To download a copy of Mobile Consumer Engagement 2020, visit https://www.sinch.com/insights/downloads-and-reports/mobile-consumer-engagement-2020/

Sinch provides cloud-based connections between businesses and their customers. Through messaging, voice and video, Sinch handles 25 billion API transactions annually. Eight of the world’s 10 largest US tech enterprises (by market capitalization), as well as major airlines, rail, ridesharing and parcel delivery services around the world rely on Sinch for personalized, seamless and secure mobile connections. Find out more at Sinch.com or connect on Facebook, LinkedIn, Twitter or Instagram.

Media Contact:
Name: Jeff Hasen                                                       
Email: Jeff.Hasen@sinch.com

Attachment